Clinical Trial Update: Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update evaluating lenvatinib after liver transplantation in high-risk hepatocellular carcinoma patients (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: RenJi Hospital | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN